Print Bookmark

Injection

contraceptive injectionWhat is the contraceptive injection?

The injection contains progestogen. It is given by a doctor or nurse once every 12 weeks.

Would a contraceptive injection suit me?

The injection is a long-acting hormonal method providing effective contraception. Progestogen-only injections are also suitable for women who are breast-feeding, and those who do not tolerate estrogen. The contraceptive injection has very high reliability when used properly.

Injections may also reduce heavy painful periods and help reduce premenstrual symptoms. Periods and fertility may take up to a year to return after stopping injections.

Some women experience headaches, dizziness, pimples and greasy skin, bloating, weight gain, breast tenderness, abdominal discomfort, and changes in mood and sex drive. As the hormones cannot be removed from the body once the injection has been administered, side effects may continue from the time of the injection and for some time afterwards. With the progestogen-only injection women may have a risk of losing bone mineral density which may increase the risk of osteoporosis.

What other long-term contraceptive might suit me?

There are four long-term contraceptives. Please see below the comparison chart to see which of these option may be suitable for you.


FAILURE RATE

FAILURE RATE

FAILURE RATE

FAILURE RATE

2| 1,000WOMEN(number of pregnancies after one year of use)1
6-8| 1,000WOMEN(number of pregnancies after one year of use)1
2-60| 1,000WOMEN(number of pregnancies after one year of use)1
< 1| 1,000WOMEN(number of pregnancies after one year of use)1

ADMINISTRATION

ADMINISTRATION

ADMINISTRATION

ADMINISTRATION

Placement in womb2
Placement in womb3
Injection in arm or buttock4
Placement under the skin of arm5

LENGTH OF PROTECTION

LENGTH OF PROTECTION

LENGTH OF PROTECTION

LENGTH OF PROTECTION

Up to 5 years1
Up to 5 to 10 years, depending on model3,6
12 weeks5
Up to 3 years1

RETURN TO FERTILITY

RETURN TO FERTILITY

RETURN TO FERTILITY

RETURN TO FERTILITY

No delay7
No delay7
Possible delay of up to 1 year following treatment cessation7
No delay7

MENSTRUAL BLEEDING

MENSTRUAL BLEEDING

MENSTRUAL BLEEDING

MENSTRUAL BLEEDING

  • Initially periods may be lighter or heavier, longer or shorter or absent.2
  • Infrequent or absent periods likely after several months.2
  • Bleeding and spotting days may increase in first few months.3
  • Bleeding may be heavier.3
  • Irregular and possibly lengthy bleeding or spotting or no bleeding at all.4
  • Periods may become more or less frequent, continuous or absent.5
  • May reduce or increase in intensity or duration.5

BODY WEIGHT

BODY WEIGHT

BODY WEIGHT

BODY WEIGHT

No effect7
No effect7
May cause weight gain of 2.3 – 3.6 kg in the first year4,7
No effect7

USE DURING BREASTFEEDING

USE DURING BREASTFEEDING

USE DURING BREASTFEEDING

USE DURING BREASTFEEDING

  • Yes2
  • 6 weeks after birth2
  • Yes3
  • 6 weeks after birth3
  • Yes4
  • 6 weeks after birth4
  • Yes5
  • 4 weeks after birth5

HEAVY PERIOD TREATMENT

HEAVY PERIOD TREATMENT

HEAVY PERIOD TREATMENT

HEAVY PERIOD TREATMENT

Yes8
No3
No4
No5

USE IN ESTROGEN THERAPY

USE IN ESTROGEN THERAPY

USE IN ESTROGEN THERAPY

USE IN ESTROGEN THERAPY

Yes – May be used in conjuction with estrogen as hormonal replacement therapy (HRT)8
No – Not recommended for use as hormonal replacement therapy (HRT)3

No – Not recommended for use as hormonal replacement therapy (HRT)4

No – Not recommended for use as hormonal replacement therapy (HRT)5

1. Trussell J. Contraceptive failure in the United States. Contraception 83 (2011) 397–404. 2. Package leaflet: information for the user. Mirena: Corporate Patient Information. Bayer Schering Pharma. January, 2011. 3. Nova T – Copper Containing Intrauterine Device. Patient Information. Bayer Schering Pharma AG, November 2008. 4. Depo-Provera patient information leaflet. Pharmacia. August 2010. 5. Nexplanon – information for the user. Patient Information. July 2010. http://www.nexplanon.co.uk 6. Paragard T380A Prescribing Information. Duramed Pharmaceuticals, INC. 2006. http://www.paragard.com 7. Long-acting reversible contraception – the effective and appropriate use of long-acting reversible contraception. National Collaborating Centre for Women’s and Children’s Health. Commissioned by the National Institute for Health and Clinic Excellence, October 2005. Published by RCOG Press. ISBN 1-904752-18-7. 8. Mirena: The intrauterine system. Product Monograph. Bayer Schering Pharma. 2009. ISBN 978-1-904667-09-4.